Publications

Publications keep interested parties informed about the latest scientific, clinical, trial-based, and peer-reviewed documentation about our products and pipeline. Find the latest below:

Publications
Sort by :
2026 cardiometabolic

Expanding Patient Choice in Diabetes Care: Reducing Access Barriers to Inhaled Insulin

Diabetes Technology & Therapeutics
Published Online: October 19, 2026
2026 cardiometabolic

Experiences With Inhaled Insulin in a Real-World Sample of Adults With Type 1 Diabetes in the T1D Exchange Registry

The Science of Diabetes Self-Management and Care
September 7, 2026, Volume 52, Issue 5, Pages 393-405
2026 cardiometabolic

Inhaled Insulin Dosing in a Randomized Trial in Adults With Type 1 Diabetes

AACE Endocrinology and Diabetes
May-June 2026, Volume 13 Issue 3, Pages 428-435
2026 cardiometabolic

Inhaled Technosphere Insulin Reduces Postmeal Glucose Excursion in Youth Living with Type 1 Diabetes

Diabetes Technology & Therapeutics
Published Online: March 14, 2026
2026 cardiometabolic

Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study

Diabetes Technology & Therapeutics
Published Online: February 4, 2026
2026 cardiometabolic

Role of Ultra-Rapid Acting Insulin in Managing Diabetes

Diabetes Technology & Therapeutics
February 1, 2026, Volume 28 Issue 1 Pages 1S – 5S
2026 cardiometabolic

30 Years of Developing Inhaled Insulin

Diabetes Technology & Therapeutics
February 1, 2026, Volume 28 Issue 1 Pages 6S – 7S
2026 cardiometabolic

Dosing Afrezza: It's Not that Complicated

Diabetes Technology & Therapeutics
February 1, 2026, Volume 28 Issue 1 Pages 8S – 13S
2026 cardiometabolic

Unmet Needs in Insulin-Treated Diabetes Management

Diabetes Technology & Therapeutics
February 1, 2026, Volume 28 Issue 1 Pages 14S – 18S
2026 cardiometabolic

Pulmonary Safety and Clinical Considerations for Inhaled Insulin: A Comprehensive Review

Diabetes Technology & Therapeutics
February 1, 2026, Volume 28 Issue 1 Pages 19S – 25S
2026 cardiometabolic

Impact of Inhaled Insulin Therapy on Hypoglycemia

Diabetes Technology & Therapeutics
February 1, 2026, Volume 28 Issue 1 Pages 26S – 30S
2026 cardiometabolic

Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations

Diabetes Technology & Therapeutics
February 1, 2026, Volume 28 Issue 1 Pages 31S – 37S
Sort by :
2025 cardiometabolic

Safety and Efficacy of Inhaled Technosphere® Insulin in the Postprandial Period With Modified Initial Dose Conversion

Diabetes Therapy
June 18, 2025, Volume 16 Pages 1695-1705
2025 cardiometabolic

A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes

Diabetes Technology & Therapeutics
March 18, 2025, Volume 27 Issue 3 161-169
2025 cardiometabolic

Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes: The INHALE-3 Extension Study

Diabetes Technology & Therapeutics
March 18, 2025, Volume 27 Issue 3 170-178
2025 cardiometabolic

Pharmacokinetics and Pharmacodynamics of a Novel Formulation of Furosemide Administered as a Single Subcutaneous Injection

CLINICAL THERAPEUTICS
2025; Oct 14:S0149-2918(25)00310-8
2025 cardiometabolic

An Adult Population Pharmacokinetic Model to Simulate Subcutaneous Administration of a Fixed Dose of Furosemide in Adolescents with Heart Failure and Volume Overload.

CLINICAL PHARMACOKINETICS
2025; 64(6): 899–908.
2025 cardiometabolic

A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes

DIABETES CARE
2025; 48(3); 353-360
2025 cardiometabolic

Safety and Efficacy of Inhaled Technosphere® Insulin in the Postprandial Period With Modified Initial Dose Conversion

Diabetes Therapy
2025
2024 cardiometabolic

A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Using Multiple Daily Injections of Insulin or Automated Insulin Delivery

DIABETES CARE
2024;47(9):1682-1687
2024 cardiometabolic

Human Factors Validation of a Wearable, On-Body Infusor for Subcutaneous Administration of Furosemide.

MEDICAL DEVICES: EVIDENCE AND RESEARCH
2024; June 24;17: 229-235.
2024 cardiometabolic

Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial.

EUROPEAN JOURNAL HEART FAILURE
2024; 27(2): 347-352.
2024 cardiometabolic

Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF).

JACC HEART FAILURE
2024; 12(11): 1830-1841.
2023 cardiometabolic

Examining the Burden of Potentially Avoidable Heart Failure Hospitalizations

CLINICOECONOMICS AND OUTCOMES RESEARCH
2023; Sep 29;15: 721-731.